Astellas Pharma Inc. has had minor involvement with vaccines in recent years. But in late 2013, the firm in-licensed worldwide rights for Mymetics Corp.’s preclinical respiratory syncytial virus vaccine. Astellas is developing the vaccine through RSV Corp., a company it formed with support from ClearPath Development Co. in December 2013 [See Deal].
ClearPath is supporting Astellas in identifying and developing vaccine candidates. Each vaccine candidate that goes through the partnership will likely be housed in its own start-up company
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?